Cagrilintide vs Petrelintide
How Cagrilintide and Petrelintide compare — what each is, how strong the human evidence is for each, doses reported in research, the key risks, and 2026 US legal status. No universal winner.
Cagrilintide and Petrelintide come up together when people are weighing similar options. Here's the honest side-by-side: what each is, how strong the human evidence is for each, the doses reported in research, the risks, and where each stands with the FDA as of 2026. There's no universal winner — scroll to the by-goal picks for which one fits which goal.
Cagrilintide vs Petrelintide, point by point
Every dimension side by side — the honest differences, not a scoreboard.
| Dimension | Cagrilintide | Petrelintide |
|---|---|---|
| What it is | Long-acting amylin analogue (a lipidated, modified synthetic version of the pancreatic hormone amylin) | Long-acting synthetic human amylin analog |
| Class / category | Incretin / metabolic | Incretin / metabolic |
| Evidence tier | Human RCT · Helped | Human RCT · Helped |
| Studied / approved for | Weight management / obesity; Type 2 diabetes (as part of CagriSema) | Chronic weight management; Weight management in people with type 2 diabetes |
| US regulatory status (2026) | investigational (as of Jul 2026) | investigational (as of Jul 2026) |
| Doses reported in research | No established study doses | No established study doses |
| Registered trials (ClinicalTrials.gov) | 42 | No data |
| Banned in sport (WADA) | Yes — on the WADA prohibited list | Yes — on the WADA prohibited list |
| Key risks | Cagrilintide's side-effect profile in trials looks a lot like the GLP-1 drugs it's often paired with: mostly gastrointestinal — nausea, vomiting, diarrhea, constipation — plus injection-site reactions, usually mild to moderate and worst while the dose is being increased. Because it is still investigational, long-term human safety data are limited, and the research-market powder sold online is unregulated for purity and sterility. | ZUPREME-1 found similar overall adverse-event and serious-adverse-event rates with pooled petrelintide and placebo, but nausea was more common with petrelintide. Most gastrointestinal events were mild. One 51-week Phase 2 trial cannot establish long-term safety, rare harms, or safety in routine care. |
- Evidence tier: A tier reflects how human the evidence is, not a promise the compound works.
Cagrilintide vs Petrelintide: the two molecules
The 2D chemical structures, straight from PubChem — a quick way to see how similar (or not) the two actually are.
Which one fits which goal?
There's no universal winner here — the honest answer depends on what you're after. These picks are framed by goal, and each says why.
Which one fits your goal
These two overlap enough that the honest call comes down to your specific goal and how much human evidence you want before trying something. Compare the differences in the table above — there's no universal winner here.
References
- 1.Cagrilintide — indexed research (PubMed, National Library of Medicine)
- 2.Cagrilintide — registered clinical studies (ClinicalTrials.gov)
- 3.REDEFINE 1 — CagriSema in people with excess body weight (ClinicalTrials.gov NCT05567796)
- 4.FDA — Drugs (approval status lookup)
- 5.Novo Nordisk files for FDA approval of CagriSema
- 6.Novo Nordisk reports headline results from REDEFINE 4